After adjustment for age, sex, ethnicity, smoking status, tumor histology, Karnofsky's performance scores, tumor stage, application of chemotherapy and radiotherapy dose, the TNFRSF1B +676 GG variant homozygous genotype remained to be associated with a significantly decreased risk of death from NSCLC (adjusted HR = 0.38, 95% CI = 0.15-0.94 for GG vs. TT; adjusted HR = 0.35, 95% CI = 0.14-0.88 for GG vs. GT/TT), but this association was not observed for the other four SNPs investigated in this study. Here, TNFRSF1B is linked to neoplasm.